For the quarter ended December 2025, Techne (TECH) reported revenue of $295.88 million, down 0.4% over the same period last year. EPS came in at $0.46, compared to $0.42 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $292.03 million, representing a surprise of +1.32%. The company delivered an EPS surprise of +8.24%, with the consensus EPS estimate being $0.43.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Growth - Diagnostics and Spatial Biology: 3% versus the two-analyst average estimate of 3.9%.
- Organic Growth - Protein Sciences: -1% versus -2.2% estimated by two analysts on average.
- Net Sales- Diagnostics and Spatial Biology: $81.18 million compared to the $81.4 million average estimate based on three analysts.
- Net Sales- Protein Sciences: $215.08 million versus the three-analyst average estimate of $207.1 million. The reported number represents a year-over-year change of +1.7%.
- Net Sales- Intersegment revenue: $-0.39 million versus the two-analyst average estimate of $-0.45 million. The reported number represents a year-over-year change of -23.2%.
View all Key Company Metrics for Techne here>>>
Shares of Techne have returned -1% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Techne Corp (TECH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
